INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2023. The put-call ratio across all filers is 2.22 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,844,782 | +104.0% | 677,329 | +170.5% | 0.02% | +112.5% |
| Q2 2023 | $1,394,550 | -10.5% | 250,368 | -7.9% | 0.01% | -27.3% |
| Q1 2023 | $1,557,414 | +445.7% | 271,800 | 0.0% | 0.01% | +1000.0% |
| Q4 2022 | $285,390 | -60.8% | 271,800 | 0.0% | 0.00% | -75.0% |
| Q3 2022 | $728,000 | -43.8% | 271,800 | 0.0% | 0.00% | -80.0% |
| Q2 2022 | $1,296,000 | +3061.0% | 271,800 | +2618.0% | 0.02% | +1900.0% |
| Q1 2022 | $41,000 | -54.9% | 10,000 | -25.3% | 0.00% | 0.0% |
| Q4 2021 | $91,000 | -88.9% | 13,390 | -81.1% | 0.00% | -66.7% |
| Q3 2021 | $819,000 | +303.4% | 70,700 | +589.8% | 0.00% | +200.0% |
| Q1 2021 | $203,000 | -4.2% | 10,250 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $212,000 | -21.2% | 10,250 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $269,000 | – | 10,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |